Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Opinion
  • Published:

Does PPI therapy predispose to Clostridium difficile infection?

Nature Reviews Gastroenterology & Hepatology volume 6, pages 555–557 (2009)Cite this article

Abstract

Clostridium difficile infection (CDI) has emerged as a problem of epidemic proportions. Previous exposure to broad-spectrum antibiotics remains the most important predisposing factor for the disease. However, PPIs are increasingly being overprescribed and recent research has, therefore, focused on the association between PPI therapy and CDI. While the data remain observational, increasing evidence exists for at least a modest association between PPI use and CDI.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Archibald, L. K., Baurjee, S. H. & Jarvis, W. R. Secular trends in hospital acquired C. diff disease in the US from 1987–2001. J. Infect. Dis. 189, 1585–1589 (2004).

    Article  Google Scholar 

  2. Fekety, R. & Shah, A. B. Diagnosis and treatment of Clostridium difficile colitis. JAMA 269, 71–75 (1993).

    Article  CAS  Google Scholar 

  3. Miller, M. A. et al. Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infect. Control Hosp. Epidemiol. 23, 137–140 (2002).

    Article  Google Scholar 

  4. Kyne, L., Hamel, M. B., Polavaram, R. & Kelly, C. P. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin. Infect. Dis. 34, 346–353 (2002).

    Article  Google Scholar 

  5. Deshpande, A., Pant, C., Jain, A., Fraser, T. G. & Rolston, D. D. Do fluoroquinolones predispose patients to Clostridium difficile associated disease? A review of the evidence. Curr. Med. Res. Opin. 24, 329–333 (2008).

    Article  Google Scholar 

  6. O'Connor, J., Johnson, S. & Gerding, D. C. diff infection caused by the epidemic B1/NAP1/O27 strain. Gastroenterology 136, 1913–1924 (2009).

    Article  CAS  Google Scholar 

  7. Bartlett, J. & Perl, T. The new Clostridium difficile—what does it mean? N. Engl. J. Med. 353, 2503–2505 (2005).

    Article  CAS  Google Scholar 

  8. Cunningham, R. & Dial, S. Is overuse of proton pump inhibitors fueling the current epidemic of Clostridium difficile associated diarrhea? J. Hosp. Infect. 70, 1–6 (2008).

    Article  CAS  Google Scholar 

  9. Williams, C. & McColl, K. E. Review article: proton pump inhibitors and bacterial overgrowth. Aliment. Pharmacol. Ther. 23, 3–10 (2006).

    Article  CAS  Google Scholar 

  10. Jump, R. L., Pultz, M. J. & Donskey, C. J. Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea? Antimicrob. Agents Chemother. 51, 2883–2887 (2007).

    Article  CAS  Google Scholar 

  11. Dial, S., Delaney, J. A., Barkun, A. N. & Suissa, S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 294, 2989–2995 (2005).

    Article  CAS  Google Scholar 

  12. Louie, T. J. & Meddings, J. Clostridium difficile infection in hospitals: risk factors and responses. CMAJ 171, 45–46 (2004).

    Article  Google Scholar 

  13. Walker, K. J. et al. Clostridium difficile colonization in residents of long-term care facilities: prevalence and risk factors. J. Am. Geriatr. Soc. 41, 940–946 (1993).

    Article  CAS  Google Scholar 

  14. Shah, S., Lewis, A., Leopold, D., Dunstan, F. & Woodhouse, K. Gastric acid suppression does not promote clostridial diarrhoea in the elderly. QJM 93, 175–181 (2000).

    Article  CAS  Google Scholar 

  15. Lowe, D. O., Mamdani, M. M., Kopp, A., Low, D. E. & Juurlink, D. N. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. Clin. Infect. Dis. 43, 1272–1276 (2006).

    Article  CAS  Google Scholar 

  16. Pepin, J. et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin. Infect. Dis. 41, 1254–1260 (2005).

    Article  CAS  Google Scholar 

  17. Muto, C. A. et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect. Control Hosp. Epidemiol. 26, 273–280 (2005).

    Article  Google Scholar 

  18. Al-Tureihi, F. I., Hassoun, A., Wolf-Klein, G. & Isenberg, H. Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients. J. Am. Med. Dir. Assoc. 6, 105–108 (2005).

    Article  Google Scholar 

  19. Cunningham, R., Dale, B., Undy, B. & Gaunt, N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J. Hosp. Infect. 54, 243–245 (2003).

    Article  CAS  Google Scholar 

  20. Dial, S., Alrasadi, K., Manoukian, C., Huang, A. & Menzies, D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case–control studies. CMAJ 171, 33–38 (2004).

    Article  Google Scholar 

  21. Dial, S., Delaney, J. A., Schneider, V. & Suissa, S. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ 175, 745–748 (2006).

    Article  Google Scholar 

  22. Yearsley, K. A. et al. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhea. Aliment. Pharmacol. Ther. 24, 613–619 (2006).

    Article  CAS  Google Scholar 

  23. Leonard, J., Marshall, J. K. & Moayyedi, P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am. J. Gastroenterol. 102, 2047–2056 (2007).

    Article  Google Scholar 

  24. Weiss, K. Poor infection control, not fluoroquinolones, likely to be primary cause of Clostridium difficile associated diarrhea outbreaks in Quebec. Clin. Infect. Dis. 42, 725–727 (2006).

    Article  Google Scholar 

  25. Cadle, R. M., Mansouri, M. D., Logan, N., Kudva, D. R. & Musher, D. M. Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am. J. Health Syst. Pharm. 64, 2359–2363 (2007).

    Article  CAS  Google Scholar 

  26. Nardino, R. J., Vender, R. J. & Herbert, P. N. Overuse of acid-suppressive therapy in hospitalized patients. Am. J. Gastroenterol. 95, 3118–3122 (2000).

    Article  CAS  Google Scholar 

  27. NHS National Institute of Health and Clinical Excellence. Dyspepsia: managing dyspepsia in adults in primary care [online].

  28. Sandvik, A. K., Brenna, E. & Waldum, H. L. Review article: the pharmacological inhibition of gastric acid secretion—tolerance and rebound. Aliment. Pharmacol. Ther. 11, 1013–1018 (1997).

    Article  CAS  Google Scholar 

  29. Dalton, B. R., Lye-Maccannell, T., Henderson, E. A., Maccannel, D. R. & Louie, T. J. Proton pump inhibitors (PPI) significantly increase the risk of Clostridium difficile infection in a low endemicity, non-outbreak hospital setting: optimizing risk and benefit of PPI therapy. Aliment Pharmacol. Ther. 29, 626–634 (2008).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Louisiana State University Health Sciences Center and Overton Brooks VA Medical Center, Shreveport, LA, USA

    Chaitanya Pant, Phillip Madonia & Anil Minocha

Authors
  1. Chaitanya Pant
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Phillip Madonia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anil Minocha
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anil Minocha.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pant, C., Madonia, P. & Minocha, A. Does PPI therapy predispose to Clostridium difficile infection?. Nat Rev Gastroenterol Hepatol 6, 555–557 (2009). https://doi.org/10.1038/nrgastro.2009.128

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2009.128

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing